MARKET

RNA

RNA

Avidity Biosciences, Inc.
NASDAQ
72.90
+0.08
+0.11%
After Hours: 72.90 0 0.00% 17:43 02/06 EST
OPEN
72.92
PREV CLOSE
72.82
HIGH
72.95
LOW
72.79
VOLUME
3.28M
TURNOVER
--
52 WEEK HIGH
73.06
52 WEEK LOW
21.51
MARKET CAP
11.28B
P/E (TTM)
-17.4841
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Avidity Biosciences (RNA)
TipRanks · 4d ago
Avidity Plans Spin-Off Amid Novartis Acquisition Agreement
TipRanks · 4d ago
*Avidity Biosciences Sets Feb. 12 as Record Date for Spinoff > RNA
Dow Jones · 5d ago
Avidity Biosciences Sets Record Date for Spin-Off Ahead of Novartis Acquisition
Reuters · 5d ago
AVIDITY BIOSCIENCES INC - RECORD DATE SET FOR FEBRUARY 12, 2026 FOR SPIN-OFF
Reuters · 5d ago
Press Release: Avidity Biosciences Announces Expected Record Date for Spin-Off
Dow Jones · 5d ago
Weekly Report: what happened at RNA last week (0126-0130)?
Weekly Report · 5d ago
Avidity Biosciences Sets February Vote on $72-per-Share Novartis Takeover and Cardiology Spin-Off
TipRanks · 01/30 22:10
More
About RNA
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.

Webull offers Avidity Biosciences Inc stock information, including NASDAQ: RNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNA stock methods without spending real money on the virtual paper trading platform.